Repurposing tromethamine as inhaled therapy to treat CF airway disease. - Wikidata - wikimedia - TriplyDB

Repurposing tromethamine as inhaled therapy to treat CF airway disease.

Repurposing tromethamine as inhaled therapy to treat CF airway disease.

http://www.wikidata.org/entity/Q37066264

about

Lung epithelial cells: therapeutically inducible effectors of antimicrobial defense.Strategies for the etiological therapy of cystic fibrosis.Acidosis exacerbates in vivo IL-1-dependent inflammatory responses and neutrophil recruitment during pulmonary Pseudomonas aeruginosa infection.

P2860

Q40091655-8E11AF0D-4E57-41E6-A34B-F9FF0D166C58 Q42650380-980CA68D-84C6-4D89-9462-2F30EC3C6D7F Q47855629-5F709F32-D1BC-4E3D-AEFA-7A67F056CF49

P2860

Repurposing tromethamine as inhaled therapy to treat CF airway disease.

http://www.wikidata.org/entity/Q37066264

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Repurposing tromethamine as inhaled therapy to treat CF airway disease.

@en

Repurposing tromethamine as inhaled therapy to treat CF airway disease.

@nl

type

label

Repurposing tromethamine as inhaled therapy to treat CF airway disease.

@en

Repurposing tromethamine as inhaled therapy to treat CF airway disease.

@nl

prefLabel

Repurposing tromethamine as inhaled therapy to treat CF airway disease.

@en

Repurposing tromethamine as inhaled therapy to treat CF airway disease.

@nl

P1433

Q37066264-E6AB023A-C130-4AA0-BDBB-140480B1E617

P1476

Q37066264-915087B0-0C96-4B67-8590-D7955CF6D75A

P2093

Q37066264-03B8332D-6A8D-4498-9A77-1C4856B666A9

Q37066264-4BBD2289-9AF0-4229-A3DF-4983426BF60D

Q37066264-78B70858-ECE0-4483-B3A3-0DB6E20B80AD

Q37066264-7C208E5E-75BD-4959-A601-4B44C9C96420

Q37066264-7FF2AF76-51D6-4353-9080-46099A9D8284

Q37066264-A2832767-2BEE-4F65-A313-D1A9C697FE5C

Q37066264-ADD50429-5DEE-41B1-B72E-BAB844B93B1C

P2860

Q37066264-04F7F126-5DEF-4EAA-AA5D-743ABDA5C0C5

Q37066264-06F9C11E-4708-40DC-87B9-2370E707B9A7

Q37066264-08C16CF4-84F0-484C-BC1F-6E35FDB82C4A

Q37066264-0F10E501-CE84-4622-B4C3-F7A3818FDE41

Q37066264-1A16EB3E-30F5-4520-BF84-8A7D25EF8F3E

Q37066264-1A85BC0A-C480-466B-98D7-46F471270013

Q37066264-1B6D522A-BA6A-42CA-8DFC-92B0E9F1C40B

Q37066264-23A14446-07B4-48B2-AFAC-584DCFEA5A50

Q37066264-250DB8C3-F12E-486B-9CF1-4B717E3BD415

Q37066264-26E647D7-FA13-462B-8B68-4F3A27D6BAE7

P31

Q37066264-569FF8A8-9224-4B93-9DD9-4B4FFDD2FA75

P356

Q37066264-5D0926F2-0CFC-4DC8-A53C-FC3344BAA0E6

P433

Q37066264-E497CCC7-7D79-47B9-B43B-24D0CD836A7A

P478

Q37066264-F4524588-140C-48E7-87FB-DB86D8A1FC03

P50

Q37066264-A6173713-0BC1-4B1E-A246-1D118FFA7FDA

Q37066264-A8ABFA6F-510D-41FE-8BE4-7D27FAE450D7

Q37066264-DFA1E1E2-309A-472F-A90E-592521CBB109

P577

Q37066264-A0B433CD-5E7F-4F44-9379-75E0EE843136

P698

Q37066264-6BA3B5BC-3204-4D42-9D7F-895862B17E07

P932

Q37066264-C855A23F-A1C8-4FBA-A01C-D1196055729C

P356

JCI.INSIGHT.87535

P1433

P1476

Repurposing tromethamine as inhaled therapy to treat CF airway disease

@en

P2093

David A Stoltz

http://www.w3.org/2001/XMLSchema#string

Jade A Rivera

http://www.w3.org/2001/XMLSchema#string

Janice L Launspach

http://www.w3.org/2001/XMLSchema#string

Kelsey A Sheets

http://www.w3.org/2001/XMLSchema#string

Michael J Welsh

http://www.w3.org/2001/XMLSchema#string

Nicholas D Gansemer

http://www.w3.org/2001/XMLSchema#string

Peter J Taft

http://www.w3.org/2001/XMLSchema#string

P2860

Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease

Molecular basis for pH-dependent mucosal dehydration in cystic fibrosis airways

Antimicrobial peptides of multicellular organisms

Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice

Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis

Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis

Cystic fibrosis and the salt controversy.

Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils.

Neonates with cystic fibrosis have a reduced nasal liquid pH; a small pilot study.

Activity of abundant antimicrobials of the human airway.

P31

scholarly article

P356

10.1172/JCI.INSIGHT.87535

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Mahmoud H Abou Alaiwa

P577

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27390778

http://www.w3.org/2001/XMLSchema#string

P932

4933331

http://www.w3.org/2001/XMLSchema#string